The primary endpoint is objective response rate, with progression-free survival a key secondary endpoint. The study includes a pre-registration step for arm determination by the molecular tumor board.
A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback